Hawkins CFO Purchases 1,290 Shares Worth $153,510
Key Points
The purchase of 1,290 shares was valued at $153,510.
The transaction size represents 1% of the total equity stake held by the executive prior to the filing.
Directly held shares increased to approximately 104,000.
Jeffrey P. Oldenkamp, Executive VP and CFO of Hawkins (NASDAQ:HWKN), purchased 1,290 shares of common stock on Aug. 27, 2026, according to a recent SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Transaction value | $153,510 |
| Shares purchased (directly held) | 1,290 |
| Post-transaction shares (directly held) | 104,000 |
| Post-transaction shares (indirectly held) | 1,561 |
| Post-transaction value | $12.4 million |
Transaction value based on SEC Form 4 weighted average purchase price ($119); post-transaction value based on Aug. 27, 2026, market close ($117.67).
Key questions
- What does this transaction indicate about executive sentiment?
The purchase of 1,290 shares at $119 per share reflects a direct increase in the CFO's personal equity exposure to Hawkins. - How are the remaining shares structured?
The executive maintains the vast majority of his holdings directly, although the filing details 1,561 shares held indirectly by an ESOP trustee. - What is the current scale of the insider's equity position?
Following this transaction, the executive holds approximately 106,000 shares, representing a 0.5% ownership interest in the company as of the Aug. 28, 2026, market close. - What role does Hawkins play in its sector?
The company serves diverse markets, including agriculture and energy, through three principal divisions: Industrial, Water Treatment, and Health and Nutrition.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-08-28) | $120.35 |
| Market Capitalization | $2.5 billion |
| Revenue (TTM) | $1.1 billion |
| Net Income (TTM) | $80.6 million |
Company Snapshot
- Hawkins formulates, produces, and distributes specialty chemicals and specialized ingredients across three principal divisions: Industrial, Water Treatment, and Health and Nutrition, generating revenue from diverse end markets including agriculture, chemical processing, electronics, energy, and food production.
- The company operates a vertically integrated business model that captures value by developing and manufacturing chemical solutions tailored to customer specifications, with revenue derived from the sale of industrial-grade chemicals, water treatment products, and nutritional ingredients to both domestic and international markets.
- Hawkins serves a diversified customer base spanning industrial manufacturers, municipal and commercial water treatment facilities, food and beverage producers, and agricultural enterprises, positioning the company as a critical supplier of specialized chemical inputs across multiple end-use industries.
Hawkins is a specialty chemicals manufacturer with a market capitalization of $2.5 billion and TTM revenue of $1.1 billion, demonstrating scale and profitability with TTM net income of $80.6 million. The company's diversified portfolio across Industrial, Water Treatment, and Health and Nutrition segments provides exposure to resilient end markets with recurring demand characteristics. As a formulator and distributor of mission-critical chemical inputs, Hawkins maintains competitive advantages through technical expertise, customer relationships, and integrated production capabilities that support customer-specific applications and supply chain reliability.
What this transaction means for investors
When an insider sells shares, it could be for a variety of reasons. When an insider buys shares, however, the main reason is typically that they believe the stock price will go up. Adding 1,290 shares signals confidence in the company from OldenKamp, who now directly holds a substantial 104,223 shares. He also indirectly holds over 1,500 shares. Given that the Hawkins stock price has dropped 12.6% over the past 12 months, this is a bullish signal for shareholders.
As for what's next for the Hawkins stock price, while it doesn't receive much analyst coverage, among those who do, there appears to be some upside ahead. According to CNN, of the three analysts who cover the stock, the median price target over the next 12 months for the stock is $177.50. At $123.79, the price as of this writing, that would represent a 43.3% gain by September 2027. The highest price target, $200, is even more bullish, representing a 61.5% gain. And even at the lowest price target of $142, it would still represent a 14.7% gain.
Jack Delaney has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.